At Circio we recognize the scientific and commercial value of collaborating with academic and industry partners at all stages of development; from discovery and preclinical stage for our circVec circular RNA platform to clinical development of cancer vaccine TG01, which targets RAS driver mutations.
Strategic focus areas
Circio´s main areas of focus are circular RNA therapeutics for gene and cell therapy and immunotherapy in oncology.
circular RNA – circVec platform
- circVec is Circio´s unique, proprietary circular RNA expression technology for enhanced gene and cell therapy.
- circVec offers 70-fold prolonged half-life and up to 15-fold increased protein expression vs. conventional mRNA-based expression systems.
- Circio is exploring the potential of circVec in various therapeutic areas including AAV gene therapy, in vivo CAR-T, DNA-based therapeutics and vaccines.
Circio is seeking circVec collaborations with companies that have expertise in:
- AAV gene therapy
- In vivo and ex vivo cell therapy
- Novel DNA vector technology
- Non-liver nucleic acid delivery technology
- Muscle and cardiac genetic disease
- Engineered or proprietary proteins or peptides suitable for vector delivery for chronic disease and cancer.
KRAS program
- TG01 is Circio’s lead cancer immunotherapy product targeting seven common RAS driver mutations, found in over 90% of pancreatic cancer, 50% of colorectal cancer and 20-30% of all cancers.
- A phase 1/2 clinical trial has demonstrated promising results for TG01 in combination with gemcitabine to treat patients with surgically resected pancreatic cancer.
- Circio is currently testing TG01 in combination with the adjuvant QS-21 STIMULON in the USA and Europe. Investigator sponsored trials in pancreatic and lung cancer are enrolling patients at Georgetown University (Washington DC, USA) and in multiple myeloma at Oslo University Hospital (Norway).
- Circio is interested in additional partnerships to test TG01 as part of novel combination strategies for mutant-RAS driven tumor types.